Consent, PPE and clinical guidance
The majority of COVID-19 vaccinations are being delivered by the primary care sector. Please refer to the Commonwealth Department of Health website for more information.
Vaccine PPE and clinical guidance documents
PPE advice for the COVID-19 vaccine rollout have been identified through review of clinical guidelines to identify the types of PPE required for different levels of risk for community transmission of COVID-19. Engagement with clinical stakeholders has also identified where PPE usage in practice may diverge from clinical guidelines.
Clinical Guidelines for Covid-19 Vaccine Medical Exemptions in Queensland
Consumers may need seek assessment for a medical exemption from the Covid-19 Vaccines for a variety of reasons. As per the Services Australia immunisation medical exemptions advice, a consumer may be able to get an exemption from having a vaccine if there is a valid medical reason. Granting medical exemptions to these COVID-19 vaccination requirements for reasons outside the ATAGI Guidelines, such as for conscientious objections, creates inequity and increases health risks, particularly to vulnerable Queenslanders. This Queensland Health Clinical Guidance has been developed by the Vaccine Command Centre and endorsed by the Covid-19 Vaccination Clinical & Technical Advisory Group (CTAG) and clearly sets out the only reasons medical exemptions may be provided in Queensland to assist you in conversations with your patients.
Information on Thrombosis with thrombocytopenia syndrome (TTS)
Thrombosis with thrombocytopenia syndrome (TTS) also known as Vaccine Induced Prothrombotic Immune Thrombocytopenia (VIPIT), Vaccine Associated Thrombosis Thrombocytopenia (VATT) and Vaccine Induced Immune Thrombotic Thrombocytopenia (VITT), is a very rare side effect associated with the Vaxzevria (AstraZeneca) COVID-19 vaccine.
Health professionals are required to complete the COVID-19 Vaccine Induced Thrombosis (TTS/VITT/VATT/VIPIT) form (PDF 749 kB) when reporting confirmed, probable or possible TTS/VITT/VATT/VIPIT. To report other suspected adverse events associated with COVID-19 vaccination, please refer to our Adverse Event Following Immunisation website.
Further information can be found on the Thrombosis and Haemostasis Society Australia and New Zealand (THANZ) website.
COVID-19 Clinical vaccination advice for cancer patients
Patients with cancer are at higher risk of morbidity and mortality following COVID-19 infection than patients with no comorbid conditions. This information from the Statewide Cancer Clinical Network will help guide vaccination decisions for clinicians and their patients.